FDA Approves Vyalev: A Breakthrough Continuous Infusion Therapy for Advanced Parkinson’s Disease

Vyalev, Parkinson’s disease, continuous infusion therapy, FDA approval, AbbVie, motor fluctuations, levodopa, carbidopa